Hints and tips:
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...Dr Robert Challen of the University of Exeter, whose modelling of the variant from India was presented to the government’s scientific advisory group, Sage, said it was hard to reach a definitive conclusion...
...The Independent Sage group of scientists issued an “emergency statement” urging the government to rule out immediately plans to lift the last restrictions on June 21....
...The AU will pay $6.75 a dose for the BioNTech/Pfizer vaccine and $10 for Johnson & Johnson’s, a single-dose product....
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
...“Delay in second dosing may contribute to this risk,” said Deenan Pillay, professor of virology at University College London and a member of Independent Sage, a UK group of scientists who offer an alternative...
...Letter in response to this article: Big Pharma can still look to England for business / From Bryn Sage, Harrogate, N Yorks, UK...
...V.me allows people to make online purchases without having to punch in their card details each time....
...The possibility of a Pfizer/AstraZeneca deal still has the politicians talking (the chief executives of both were hauled before the UK parliament this week)....
...pressure from the opposition Labour party to intervene in Pfizer’s proposed £63bn takeover of AstraZeneca....
...Bold Sage pensioner Personal and corporate objectives can collide....
...WARREN BUFFETT (aka the “Sage of Omaha”) Classic Quote: “Rule No. 1: never lose money. Rule No. 2: don’t forget rule No. 1.”...
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
...Finally, Mr O’Connor could not resist heading his note on the departure of Paul Stobart, Sage’s northern European chief executive, as D.I.V.O.R.C.E....
...Autonomy fell 3.4 per cent to £16 and Sage declined by 0.6 per cent to 280½p....
...Pfizer, the largest US drugmaker by market value, inched down 0.7 per cent to $14.54 as the stock being removed from the “conviction buy” list at Goldman Sachs....
...Last week’s US jobs report has knocked investor confidence, and those predicting a V-shaped recovery are finding it harder to justify their positions....
...This spurred groups such as Pfizer of the US and Roche of Switzerland to strike multi-billion-dollar deals during the first half of this year....
...It is hard to see how even the great sage could know this, but easy to see what he means....
...However, it was hardly a classic David v Goliath battle, given that the victor was Citigroup, the US banking giant, which is no stranger to struggles with regulators across the world....
...Kindler, Chairman and CEO, Pfizer Inc., USA Klaus Kleinfeld, President and CEO, Siemens AG, Germany Mustafa V....
...He was born in 1954, the year, as he points out, of the famous Brown v Board of Education case which paved the way for US desegregation....
International Edition